GI
CRSP icon

GAMCO Investors’s CRISPR Therapeutics CRSP Stock Holding History

GAMCO Investors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,000
Closed -$261K – 893
2022
Q3 		$261K Buy
+4,000
New +$290K ﹤0.01% 774
2021
Q3 		– Sell
-3,100
Closed -$502K – 928
2021
Q2 		$502K Buy
+3,100
New +$377K ﹤0.01% 760

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GAMCO Investors's CRSP Position: Q4 2022 in Review

GAMCO Investors sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 4,000 shares — an estimated $261K sold.

GAMCO Investors first reported a position in CRSP in Q2 2021 and held it in 2 quarters. The position peaked at $502K in Q2 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • GAMCO Investors reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • GAMCO Investors sold 4,000 CRISPR Therapeutics shares in Q4 2022, an estimated $261K.
  • GAMCO Investors first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 2 quarters.
  • GAMCO Investors's CRISPR Therapeutics position peaked at $502K in Q2 2021.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on GAMCO Investors's 13F filing for Q4 2022, filed 13 Feb 2023.